Safety
infection, deaths, GVHD
ADVERSE EVENTS, INFECTION, GVHD, MULTIPLE ORGAN FAILURE
The incidences of total treatment-emergent adverse events and treatment-emergent serious adverse events were similar in the two treatment arms (Table Nine patients (8.9%) died until data cut-off; 7 of 50 patients (14.0%) in the busulfan arm and 2 of 51 patients (3.9%) in the treosulfan arm. All deaths were transplantation related. In both arms, most common causes were infection and GVHD associated multiple organ failure (Supplementary Table 